Targeting PP2A in cancer: an underrated option
Open accessThe DOI matches its Crossref record; 287 of the 287 references it cites were found in a registry or an index; 8 of the 162 sources its claims cite were checked for support.
Abstract
Protein phosphatase 2A plays a central role in modulating multiple signaling pathways, including PI3K, EGFR, Myc, WNT, JAK/STAT, RAS/MAPK, and NF-κB, which are frequently dysregulated in cancer. Although PP2A is broadly considered a tumor suppressor due to its frequent functional loss in tumors, its biological role is highly context-dependent and varies across cancer types and stages. The activity of the heterotrimeric PP2A complex is tightly controlled by the precise assembly and composition of the scaffolding (A), catalytic (C), and variable regulatory (B) subunits, with the latter exhibiting tissue- and developmental stage-specific patterns, thus allowing PP2A to exert context-dependent effects on signaling networks. In many cancers, PP2A dysregulation arises from mutations in subunit genes, post-translational modifications, or disrupted expression, leading to impaired holoenzyme formation and loss of activity. PP2A dysfunctionality often promotes the aberrant activation of pathways, including mTOR, and the enhanced phosphorylation of own and downstream targets, such as S6 kinase, facilitating tumor growth and progression. In this review, we discuss the mechanisms of PP2A dysregulation in cancer and highlight PP2A restoration as a promising therapeutic approach.
Overview
CoChat Summary
## TL;DR
This review argues that PP2A is a context-dependent cancer target: it can act as a tumor suppressor in many settings, but some PP2A complexes or regulatory states can also support oncogenic signaling. It highlights PP2A modulators already in preclinical/clinical study and makes a special case for the brain-enriched subunit PPP2R2C/B55γ as a potential biomarker and therapeutic handle.
## Key findings
- PP2A is described as a major serine/threonine phosphatase that dephosphorylates over 300 substrates and is involved in more than 90 distinct holoenzyme assembly combinations.
- In glioma/GBM, restoration of PPP2R2C/B55γ inhibited colony formation and suppressed proliferation in both in vitro and in vivo models; B55γ overexpression also decreased S6 kinase (S6K) phosphorylation.
- In mouse models, Aα mutations or loss of B′ subunits promoted tumors: E64D/+, del5-6/+, and del5-6/E64D mice showed an approximately 50% increased lung cancer rate after benzopyrene exposure versus wild-type mice; B56δ KO animals developed malignant lymphomas and up to 60% of the oldest mice developed HCC.
- The review notes therapeutic candidates and reported effects including LB-100 potentiating CAR-T efficacy in GBM via mTORC1 activation, and DBK-061/DBK-1154 (as named in the text) reducing intracranial tumor growth and increasing survival in GBM mouse models.
## Methods
- Narrative review/overview of the PP2A literature, with a historical section, structural summary, and disease-by-disease discussion across cancers and selected neurodevelopmental disorders.
- Synthesizes published evidence from in vitro experiments, mouse knockout/knock-in models, preclinical studies, and clinical studies/trials; no new patient cohort or original experimental dataset is presented in the text provided.
- Main analysis is qualitative and mechanistic, organizing findings around PP2A structure, dysregulation, therapeutic modulation, PPP2R2C/B55γ, splice variants, biomarkers, and tumor microenvironment effects.
## Limitations
- The paper explicitly notes that the functional significance of B55γ/PPP2R2C, including its transcriptional variants and protein isoforms, is incompletely understood, and that there is little direct evidence linking specific PPP2R2C splice variants to treatment-resistant GBM or prostate cancer.
- It states that specificity and delivery efficiency remain major obstacles when targeting splicing events or abnormal RNA species at the post-transcriptional level.
- Evident from the text: this is a review, so conclusions depend on heterogeneous prior studies rather than a single standardized dataset, and many claims are context-dependent across cancer types and model systems.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Schematic representation of the PP2A holoenzyme complex and its subunits. The holoenzyme consists of three subunits: scaffolding subunit A (yellow), catalytic subunit C (pink), and regulatory subunit B (pink). The A subunit consists of 15 HEAT repeats with designated binding sites for the regulatory subunit B’ (HR2-HR8) and the C subunit (HR11-HR15), facilitating assembly and spatial organization. The C subunit features structural motifs, loops, and helix switches that contribute to conformational changes essential for enzymatic function. It also coordinates magnesium (Mg²⁺), which is critical for phosphatase activity. The B family shares a typical motif of six β-propeller (WD40) repeats, which is a sequence of 44–60 amino acids (aa), mediating cellular localization, and substrate recognition by providing a platform for protein–protein or protein–DNA interactions [39]. Created in https://www.ncbi.nlm.nih.gov/Structure/icn3d (Access on 23.04.2025)](https://figures.cochat.ai/paper-figures/54c91b6f589f48f5be34ac26ada6f872/targeting-pp2a-in-cancer-an-underrated-option-figure-2.jpg)


Verification
Claims the paper makes
7 Valid · 0 Not valid · 98 Not checked · 13 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More importantly, knockout (KO) studies in mice have revealed that the homozygous deletion of PPP2R1A and PPP2CA is embryonically lethal [ 36 – 38 ].”
What the sources say
- Partly supportedcites [36] Ruediger R, Ruiz J, Walter G. Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice. Mol Cell Biol. 2011;31:3832–44. https://doi.org/10.1128/MCB.05744-11. sourceExperimental — accuracy not yet measured
The Results section (“Requirement of Aα for embryonic development”) reports that mice homozygous for the Aα knockout allele produced no surviving pups and that development was blocked before E10.5. This supports embryonic lethality for PPP2R1A, but the cited paper does not report a PPP2CA knockout or establish its embryonic lethality. (LLM, conf=0.88)
- Not checked yetcites [37] Gu P, Qi X, Zhou Y, Wang Y, Gao X. Generation of Ppp2Ca and Ppp2Cb conditional null alleles in mouse. Genesis. 2012;50:429–36. https://doi.org/10.1002/dvg.20815. source
- Partly supportedcites [38] Götz J, Probst A, Ehler E, Hemmings B, Kues W. Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Calpha. Proc Natl Acad Sci U S A. 1998;95:12370–5. https://doi.org/10.1073/pnas.95.21.12370. sourceExperimental — accuracy not yet measured
The Results and Discussion report that no homozygous Cα-null mice were found among more than 350 offspring, supporting embryonic lethality for the PP2A Cα gene (PPP2CA). This paper does not report a PPP2R1A knockout or a combined deletion of the two genes. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Clinically relevant examples include HER2 splice variants (lacking exon 16) that confer resistance to trastuzumab [ 256 ].”
What the sources say
- Supportedcites [256] Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther. 2009;8:2152–62. https://doi.org/10.1158/1535-7163.MCT-09-0295. source
The HER2Δ16 Is a Tumor-Specific HER2 Oncogenic Isoform section identifies HER2Δ16 as a splice isoform with an exon 16 deletion. The Introduction reports that tumor cell lines expressing HER2Δ16 resist trastuzumab. The paper presents this as a preclinical finding, not a clinically verified treatment response. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the oncoprotein CIP2A blocks PP2A-B56α to stabilize c-MYC in HNC [ 195 ].”
What the sources say
- Supportedcites [195] Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51–62. https://doi.org/10.1016/j.cell.2007.04.044. source
The Results state that B56α is required to recruit PP2A to c-Myc and that CIP2A inhibits c-Myc-associated PP2A activity. In HNSCC cell lines, CIP2A depletion increased that activity and reduced c-Myc protein levels. The claim is supported as inhibition of PP2A activity, rather than a block of PP2A recruitment. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Considering the substantial involvement of PP2A in cell cycle regulation, tumor development, and various neurodevelopmental disorders, PP2A has emerged as a promising target for therapeutic approaches in cancer research.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
In the paper
“The structural diversity underpins their substrate and context specificity, enabling the selective recognition and dephosphorylation of a wide array of target proteins in different physiological settings using a limited and cost-efficient modular system [ 9 ].”
What the sources say
- Not checked yetcites [9] Wlodarchak N, Xing Y. Pp2a as a master regulator of the cell cycle. Crit Rev Biochem Mol Biol. 2016;51:162–84. https://doi.org/10.3109/10409238.2016.1143913. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
44 more claims
Create a free account to see all 118 claims and to verify the 154 references still open.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 57
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“reduced expression of both scaffold (PP2A-Aα and PP2A-Bα) and regulatory (PP2A-B′α) subunits.”
“This core enzyme combines with a variable regulatory B subunit (PP2A-B) to complete the holoenzyme”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“One notable mutation is P179R”
“arginine (R) is replaced by proline (P) at residue 179.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“this downregulation improves glucose homeostasis (favoring gluconeogenesis) by suppressing S6K phosphorylation.”
“Conversely, PPP2R2C overexpression led to decreased S6 kinase (S6K) phosphorylation”
Citations
Cites
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
GENCODE reference annotation for the human and mouse genomes
Frankish, A., Diekhans, M., Ferreira, A.-M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J. M., Sisu, C., Wright, J., Armstrong, J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky955 · Cited by 3,040
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Bialojan, C., & Takai, A. (1988) · Biochemical Journal · doi:10.1042/bj2560283 · Cited by 1,691
Alternative splicing as a regulator of development and tissue identity
Baralle, F. E., & Giudice, J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.27 · Cited by 1,333 · cited 1×
“Studies have revealed that these networks work in a coordinated manner to control tissue and organ development, playing a crucial role in various human developmental processes [252].”
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Cited by
Balancing the Edge: Phosphatases as Homeostatic Buffers of Oncogenic Kinase Signaling in Cancer
Ehm, P. A. H. (2026) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases4010004 · Cited by 2
Decreased PP2A expression and activity represent a therapeutic target for plexiform neurofibroma
Yue, M., Wang, Y., Gu, J., Zhang, C., Chen, Y., Gao, A., Choi, K., Wu, Z., Wang, Z., Pundavela, J., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02315-w · Cited by 1
Yang, P., Huang, W., Li, Q., Tu, Z., Ren, W., Shu, X., Chu, T., & Shu, P. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s568022 · Cited by 1
Murr, J., Schneider, C., Duan, N., Köse, H., Rajamani, A., He, X., Buchloh, J., Hintze, C., Naik, A., Goeke, D., et al. (2026) · MedComm · doi:10.1002/mco2.70794
Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability
Sainero‐Alcolado, L., Lama, D., Alzrigat, M., & Arsenian‐Henriksson, M. (2026) · BioDrugs · doi:10.1007/s40259-026-00798-6
Metadata
- Authors
- Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O.
- Affiliations
- Universitätsmedizin Rostock (DE)
- Corresponding author
- Shokraie, Olia
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-10-27
- Volume
- 44
- Issue
- 1
- Pages
- 295-295
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC12557939
- OpenAlex
- W4415571081
- Cited by
- 8
- References
- 287
- Citations by year
- 2026: 8
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Universitätsmedizin Rostock
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- protein phosphatase 2A, PI3K signaling, mTOR signaling, tumor suppressor function, signaling pathway dysregulation
- MeSH terms
- Animals, Humans, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Protein Phosphatase 2, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting PP2A in cancer: an underrated option. https://app.cochat.ai/papers/10.1186/s13046-025-03560-y
- The paper
- Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025). Targeting PP2A in cancer: an underrated option. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-025-03560-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.